1h Free Analyst Time
The breast cancer therapeutics market is forecasted to grow by USD 15.64 bn during 2023-2028, accelerating at a CAGR of 8.4% during the forecast period. The report on the breast cancer therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of breast cancer, robust pipeline and new drug approvals, and rising number of patient support initiatives.
The breast cancer therapeutics market is segmented as below:
By Disease Type
- Invasive breast cancers
- Ductal carcinoma in situ
By Therapy
- Targeted therapy
- Hormonal therapy
- Chemotherapy
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the breast cancer therapeutics market covers the following areas:
- Breast cancer therapeutics market sizing
- Breast cancer therapeutics market forecast
- Breast cancer therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Disease Type
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global breast cancer therapeutics market: AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, PerkinElmer Inc, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the emerging novel therapeutics.'
According to the report, one of the major drivers for this market is the rising prevalence of breast cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- Clovis Oncology Inc.
- Daiichi Sankyo Co. Ltd.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Exelixis Inc.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- Novartis AG
- PerkinElmer Inc
- Pfizer Inc.
- Puma Biotechnology Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
